GSK agreed to transfer worldwide rights to linerixibat, an investigational IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis, to Alfasigma for up to $690 million. The deal includes a $300 million upfront payment and $100 million contingent on anticipated FDA approval, with additional milestone and royalty payments. The GLISTEN phase III data supported itch reduction and sleep improvement, underpinning the transaction. GSK said the sale will sharpen its liver‑disease focus and reallocate resources to other hepatic programs. The agreement is timed to a pending FDA decision and will require customary regulatory clearances before closing.